Introduction

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, and it is a multifactorial polygenic disorder with a broad spectrum of clinical manifestations. Although pathogenesis is still unclear, androgen receptor (AR) gene polymorphism may be one of the etiologic factors of PCOS. AR gene polymorphism has been also associated with other forms of androgen pattern diseases. We report a PCOS woman with heterozygous AR gene mutation who gave birth to a baby with androgen insensitivity syndrome.

Keywords: Androgen-insensitivity syndrome; Androgen receptor gene polymorphism; Polycystic ovary syndrome
Case report

A 37-year-old Korean woman (gravida 3 and para 1) with birth history of the child with AIS was referred to our Reproductive Medicine and Infertility Clinic for infertility treatment. Her body mass index was 22.1 and Ferriman-Gallway index score for diagnosis of hirsutism was 5. She had no growth or sexual developmental abnormalities, or abnormal gynecological symptoms except oligomenorrhea with an interval of 35 to 50 days. She did not have any particular family history including diabetes and cardiovascular disease. In 2008, she was naturally pregnant and delivered a baby girl at term by cesarean section. Eight months after birth, walnut sized soft masses were palpated at both inguinal area of her baby, and the baby had undergone a herniorrhaphy under the diagnosis of bilateral inguinal hernia. In an operating room, testis- and spermatic cord-like masses were accidentally found in both inguinal canals. Therefore, this baby was referred to our Medical Genetic Center for diagnostic workup. The external genitalia showed grossly normal appearance of a baby girl. A scrotal ultrasonography (USG) and abdomino-pelvic computed tomography (CT) scan were performed, and both testes were found in both inguinal canals (Fig. 1). The uterus, vagina and ovaries were not identified in the abdomino-pelvic CT scan (Fig. 1). Under the impression of complete AIS, cytogenetic analysis for her baby was performed, and the karyotyping showed 46,XY, inv(9) (p12q13). Therefore, this baby was diagnosed as complete AIS. Her testes are scheduled to be checked regularly and removed immediately after puberty.

Genotyping for the AR gene polymorphism of the patient (mother of AIS baby) and her AIS baby was performed. DNA was extracted from peripheral leukocyte using a standard phenol-chloroform extraction method. Partial sequence of the proband eight exons and their exon-intron boundaries of AR gene was sequenced using BigDye terminator v.3.0 and ABI3130xl Genetic Analyzer (Appliedbiosystems, Forster City, CA, USA) with genomic DNA isolated from peripheral leukocyte. In AIS baby, homozygous c.2482T>C (p.Phe828Leu) mutation on exon7 was detected (Fig. 2). This proband was strongly suggestive of AIS patient from the variation of this mutation. In the µdetected and it was consistent with carrier of AIS (Fig. 2).

Routine workup for infertility and oligomenorrhea was performed in our Reproductive Medicine and Infertility Clinic. On the 3rd day of menstruation, her blood was drawn for hormonal

![Fig. 1.](image1.png) **Fig. 1.** (A) Scrotal ultrasonography performed in an androgen insensitivity syndrome baby reveals a left testis in left inguinal canal. (B) The uterus, vagina and ovaries are not shown in the abdomino-pelvic computed tomography in an androgen insensitivity syndrome baby.

![Fig. 2.](image2.png) **Fig. 2.** (A) Partial sequencing for eight exons and their exon-intron boundaries of AR of an androgen insensitivity syndrome baby shows c.2482T>C (p.Phe828Leu) mutation on exon 7. (B) Partial sequencing for AR of polycystic ovary syndrome mother of an androgen insensitivity syndrome baby reveals heterozygous c.2482T>C (p.Phe828Leu) mutation on exon 7. In the electrogram, Y means coexistence of C base and T base as heterozygote. seq, sequence; AR, androgen receptor.
assay. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, thyroid stimulating hormone, thyroxine, 17α-hydroxyprogesterone, cortisol, insulin-like growth factor-1, dehydroepiandrosterone, glycosylated hemoglobin, and insulin were 2.9 mIU/mL, 2.1 mIU/mL, 4.6 ng/mL, 0.63 µU/mL, 1.2 ng/dL, 0.96 ng/mL, 13.9 µg/dL, 104 ng/mL, 924 ng/mL, 5.2% and 2.3 µU/mL respectively, all of which were within normal ranges. However, serum anti müllerian hormone level was 9.42 ng/mL, which was in 90 to 100 percentile of reproductive aged women. Also, serum testosterone and free testosterone concentrations were 0.58 ng/mL and 0.85 pg/mL respectively, which represented hyperandrogenemia in female based on the reference values of our institute. Transvaginal USG performed on the 7th and 14th day of menstruation showed a normal retroverted uterus and both ovaries with polycystic ovary morphology. Both right and left ovaries contained 15 follicles measuring 2-9 mm in diameter per each ovary and increased ovarian volume of 12.5 and 10.8 mL, respectively. Dominant follicle more than 10 mm in a mean diameter, corpus luteum or abnormal cyst was not identified. Doppler USG on the intraovarian arteries revealed decreased resistance index of 0.48 in each ovary. Therefore, she was diagnosed as a PCOS based on the revised PCOS diagnostic criteria of the 2003 Rotterdam consensus [10]. She is currently getting in vitro fertilization treatment for preimplantation genetic diagnosis.

**Discussion**

PCOS is a multifactorial heterogenous disorder with a strong genetic component that is characterized by hyperandrogenemia and/or insulin resistance, ultimately leading to ovulatory dysfunction including amenorrhea and oligomenorrhea, polycystic ovarian morphology and infertility [1,2]. Although its pathophysiology is not fully understood, androgen excess is considered to be an important feature of PCOS and arise primarily from dysregulated ovarian androgen secretion. We still do not know clearly what brings hyperandrogenic status in this disorder, but AR gene polymorphism has been reported to be a promising association factor and biomarker for PCOS or ovarian androgen excess [4-7].

In AR gene located in the Xq11-12, protein coding region (about 2,757 Kp open reading frame) comprises 8 exons, designated A-H or 1-8, separated by introns up to 26 kb in size. Exon 1 encodes the amino-terminal domain which comprises more than half of the AR protein. Toward the 5′end of exon 1 is a CAG repeat region (polyglutamine, PolyQ) that contains a mean repeat number of 21±2, and this repeat region is highly polymorphic [3]. Especially AR CAG repeat length may be important in the etiology of PCOS, and it seems to contribute to individual differences in the susceptibility to the development of PCOS. In general, AR polymorphism might not be a major risk factor for PCOS. However, in the present case, heterozygous c.2482T>C (p.Phe828Leu) mutation of AR gene is thought to be a possible etiologic factor or one of etiologic factors of PCOS, because this AR gene mutation transmitted from PCOS mother resulted in an AIS by androgen resistance in her baby and any other risk factors for PCOS were not found in this patient. That is to say that c.2482T>C (p.Phe828Leu) mutation of AR gene can be a cause of androgen resistance in AR and PCOS and it is proven by an AIS baby with AR gene mutation inherited from this patient. Therefore, not only CAG repeat length variation but also point mutation in AR gene can be a contributing genetic factor for PCOS.

AR gene polymorphism is also associated with the development of different androgen pattern disease including Kennedy's spinal and bulbar muscular atrophy [11]. AIS characterized by loss of AR function and variable defects in virilization of 46, XY individuals can be also caused by AR gene mutations [8]. Since AIS, so called testicular feminization was first described by Morris in 1953 [12], underlying causes have been explored. AIS is associated with various molecular defects including point mutations resulting in amino acid substitution or premature stop codon, alteration of CGA repeat number, complete or partial gene deletions and intronic mutations. Recently, Werner et al. [13] documented experimentally the contradictory effect of the combination of a short polyglycine repeat with the rare mutation of the hinge region A645D, resulting in seriously reduced AR activity when paired with a long PolyQ (CAG repeat) repeat and almost wild-type AR activity when paired with a short PolyQ repeat [13]. In this case, homozygous c.2482T>C (p.Phe828Leu) mutation on exon7 was identified from the AIS baby (Fig. 2). This mutation has not been reported for AIS, but this mutation is most likely to be a cause of AIS. This mutation of an affected baby was thought to be inherited from her carrier mother with PCOS. Actually, identified mutations of the AR gene may be recurrent, and approximately 70% of AIS patients inherit the mutation [9]. Whereas about one third are developed by de novo germline or somatic mutations.

In gynecological endocrinologic field, we can encounter a variety of endocrine disorders representing hyperandrogenism. Gynecological endocrinopathies characterized by hyperandrogenism such as PCOS can share the specific molecular de-
ffects like AR mutations with other forms of androgen pattern disease such as AIS. This case demonstrated that in PCOS patients with hyperandrogenism caused by AR gene mutations, their genetic defects can be inherited to their offspring and lead to the development of AIS. The present case suggests that the heritability of AR gene mutations in PCOS patients should be considered despite a rare possibility of comorbidity of AIS carrier and PCOS.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**References**

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-61.
2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36.
3. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-6.
4. Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:161-5.
5. Ferk P, Perme MP, Teran N, Gersak K. Androgen receptor gene (CAG)n polymorphism in patients with polycystic ovary syndrome. Fertil Steril 2008;90:860-3.
6. Skrgatic L, Baldani DP, Cerne JZ, Ferk P, Gersak K. CAG repeat polymorphism in androgen receptor gene is not directly associated with polycystic ovary syndrome but influences serum testosterone levels. J Steroid Biochem Mol Biol 2012;128:107-12.
7. Lin LH, Baracat MC, Maciel GA, Soares JM Jr, Baracat EC. Androgen receptor gene polymorphism and polycystic ovary syndrome. Int J Gynaecol Obstet 2013;120:115-8.
8. Brown TR, Lubahn DB, Wilson EM, Joseph DR, French FS, Migeon CJ. Deletion of the steroid-binding domain of the human androgen receptor gene in one family with complete androgen insensitivity syndrome: evidence for further genetic heterogeneity in this syndrome. Proc Natl Acad Sci U S A 1988;85:8151-5.
9. Galani A, Kitsiou-Tzeli S, Sofokleous C, Kanavakis E, Kali pini-Mavrou A. Androgen insensitivity syndrome: clinical features and molecular defects. Hormones 2008;7:217-29.
10. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
11. Beitel LK, Scanlon T, Gottlieb B, Trifiro MA. Progress in Spinobulbar muscular atrophy research: insights into neuronal dysfunction caused by the polyglutamine-expanded androgen receptor. Neurotox Res 2005;7:219-30.
12. Morris JM. The syndrome of testicular feminization in male pseudohermaphrodites. Am J Obstet Gynecol 1953;65:1192-211.
13. Werner R, Holterhus PM, Binder G, Schwarz HP, Morlot M, Struve D, et al. The A645D mutation in the hinge region of the human androgen receptor (AR) gene modulates AR activity, depending on the context of the polymorphic glutamine and glycine repeats. J Clin Endocrinol Metab 2006;91:3515-20.